Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer
Key facts
- Where
- Aalborg, Aarhus N, Herlev és Vejle, DániaSee the 4 sites
- Phase
- 2. fázis
Where in Dánia
- Aalborg University HospitalAalborg, DániaToborzás még nem indult
- Region MidtjyllandAarhus N, DániaToborzás még nem indult
- Region HovedstadenHerlev, DániaToborzás még nem indult
- Sygehus Lillebaelt - Vejle SygehusVejle, DániaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Hovedstaden
- Trial code
- EU 2025-522431-34-00
- Record updated
- 2026. május 18.
- Original description
To compare the efficacy of molecularly tailored therapy versus standard of care in patients with pancreatic cancer with actionable reimbursed druggable molecular alterations as measured by progression-free survivalRead full original descriptionShow less
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
To compare the efficacy of molecularly tailored therapy versus standard of care in patients with pancreatic cancer with actionable reimbursed druggable molecular alterations as measured by progression-free survival
Inclusion: Adult patients (aged 18 and over); Pancreatic cancer confirmed by cytology or histology; Written informed consent before any specific study procedures; Available personalized report communicating the molecular testing results and detailed treatment options; Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment; ECOG Performance Status 0-2; Participants must have normal organ and marrow function as defined below: - Absolute neutrophil count ≥ 1.5 x 10⁹/L - Platelet count ≥ 75 x 10⁹/L - Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) - AST/ALT ≤ 5 x ULN - Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (using the Cockcroft-Gault formula); Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in the protocol; Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year.
Exclusion: Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results; Allergies and Adverse Drug Reaction - History of allergy to study drug components - Hypersensitivity to the active substances; WOCBP who are pregnant or breastfeeding.